← Leaderboards
Andrea Viale
University Of Tx Md Anderson Can Ctr
$2,258,753
Attributed
$2,258,753
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $460K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,258,753 · 1
By mechanism
R01$2,258,753 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Marina Y Konopleva$11,210,192
- Kathleen Marie Schmainda$14,483,193
- Christopher Chad Quarles$12,985,497
- Albert Koong$7,304,561
- Francisco Vega-Vazquez$2,004,047
Others in their field
Other Emerging Leaders on “Aftercare”
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,888,963
- Bronwen Shaw · Medical College Of Wisconsin$19,182,557
- Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai$13,559,983
- Ki Young Chung · Prisma Health - Upstate$8,495,983
- Deanna A Kulpa · Emory University$8,444,989
Research focus
Aftercare3-DimensionalArchitectureBiological MarkersAnimalsCellsChemoresistanceChemotherapyClinical InvestigationClinical TrialsComplexDesignDiagnosisDisease RemissionDrug ResistanceEarly DiagnosisEcosystemEpigenomicsFaceFoundationsGemcitabineGenetic VariationGenomicsHeterogeneity
Grant awards (5)
Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer$460,031
R01 · FY2025 · CA · contact PI
Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer$437,031
R01 · FY2024 · CA · contact PI
Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer$450,830
R01 · FY2023 · CA · contact PI
Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer$450,830
R01 · FY2022 · CA · contact PI
Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer$460,031
R01 · FY2021 · CA · contact PI